Anavex Life Sciences (AVXL) Assets (2011 - 2025)

Anavex Life Sciences (AVXL) has 15 years of Assets data on file, last reported at $133.0 million in Q4 2025.

• For the quarter ending Q4 2025, Assets rose 7.21% year-over-year to $133.0 million; the trailing twelve-month figure through Dec 2025 stood at $133.0 million (up 7.21% YoY), and the FY2025 full-year result was $103.8 million, down 23.42% from the prior year.
• Assets advanced to $133.0 million in Q4 2025, from $103.8 million in the prior quarter.
• In the past five years, Assets ranged from a high of $166.4 million in Q2 2021 to a low of $83.6 million in Q1 2021.
• A 5-year average of $140.6 million and a median of $148.2 million in 2022 frame the typical range for Assets.
• Across the five-year window, Assets soared 426.14% in 2021 and slipped 27.63% in 2025, its largest moves.
• Tracing AVXL's Assets over 5 years: stood at $156.9 million in 2021, then decreased by 5.43% to $148.4 million in 2022, then dropped by 0.2% to $148.1 million in 2023, then decreased by 16.23% to $124.0 million in 2024, then gained by 7.21% to $133.0 million in 2025.
• Business Quant data shows AVXL's Assets at $133.0 million in Q4 2025, $103.8 million in Q3 2025, and $102.4 million in Q2 2025.